

**Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab)
Recombinant Antibody
Catalog # APR10599****Specification****Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	P29965
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) - Additional Information**Target/Specificity**

TNFSF5 / CD40L / CD154

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Storage

-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) - Protein Information**Name** CD40LG**Synonyms** CD40L, TNFSF5, TRAP**Function**Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed: [1280226](http://www.uniprot.org/citations/1280226), PubMed: [31331973](http://www.uniprot.org/citations/31331973)). Costimulates T-cell proliferation and cytokine production (PubMed: [8617933](http://www.uniprot.org/citations/8617933)). Its cross-linking

on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity).

Cellular Location

Cell membrane; Single-pass type II membrane protein. Cell surface

Tissue Location


Specifically expressed on activated CD4+ T- lymphocytes

Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) - Images



Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) is more than 99.24% ,determined by SEC-HPLC.